A large scale multicentre randomized, placebo-controlled subcutaneous house dust mite allergen immunotherapy (HDM SCIT) in allergic rhinitis: MITAR Study
Issued Date
2024-09-01
Resource Type
ISSN
0125877X
Scopus ID
2-s2.0-85206959656
Pubmed ID
39417769
Journal Title
Asian Pacific journal of allergy and immunology
Volume
42
Issue
3
Start Page
233
End Page
245
Rights Holder(s)
SCOPUS
Bibliographic Citation
Asian Pacific journal of allergy and immunology Vol.42 No.3 (2024) , 233-245
Suggested Citation
Suratannon N., Limsuwan T., Tantilipikorn P., Chatchatee P., Saengapaswiriya A., Boonpiyathad T., Thongngarm T., Roongpuvapaht B., Chantaphakul H., Kulalert P., Thanaviratananich S., Sangsupawanich P., Fooanant S., Manuyakorn W., Chusakul S., Piboonpochanun O., Apornpong T., Wongpiyabovorn J., Ruxrungtham K. A large scale multicentre randomized, placebo-controlled subcutaneous house dust mite allergen immunotherapy (HDM SCIT) in allergic rhinitis: MITAR Study. Asian Pacific journal of allergy and immunology Vol.42 No.3 (2024) , 233-245. 245. doi:10.12932/AP-221123-1735 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/101792
Title
A large scale multicentre randomized, placebo-controlled subcutaneous house dust mite allergen immunotherapy (HDM SCIT) in allergic rhinitis: MITAR Study
Author(s)
Author's Affiliation
Ramathibodi Hospital
Siriraj Hospital
Faculty of Medicine, Chiang Mai University
Thammasat University Hospital
Faculty of Medicine, Khon Kaen University
The HIV Netherlands Australia Thailand Research Collaboration
Phramongkutklao College of Medicine
Prince of Songkla University
Faculty of Medicine, Chulalongkorn University
Siriraj Hospital
Faculty of Medicine, Chiang Mai University
Thammasat University Hospital
Faculty of Medicine, Khon Kaen University
The HIV Netherlands Australia Thailand Research Collaboration
Phramongkutklao College of Medicine
Prince of Songkla University
Faculty of Medicine, Chulalongkorn University
Corresponding Author(s)
Other Contributor(s)
Abstract
BACKGROUND: Previous house dust mite subcutaneous immunotherapy (HDM SCIT) placebo-controlled trials have small sample sizes and lack a consensus on baseline treatment. OBJECTIVE: To determine the efficacy of HDM SCIT in moderate-to-severe allergic rhinitis (AR) patients treated with an intranasal corticosteroid at baseline. METHODS: We conducted a randomized, placebo-controlled trial comparing HDM SCIT against placebo in Dermatophagoides pteronyssinus (Der p) sensitized. All patients received standard of care according to Allergic Rhinitis and its Impact on Asthma (ARIA) guideline, including an intranasal steroid (INCS) at baseline. The primary endpoint was the comparison of a composite score, combining the total nasal symptom score and medication score, assessed at the twelfth month post-treatment. RESULTS: Of the 144 subjects, 108 received HDM-SCIT and 36 received a placebo. The median age was 30 years (range 11-61), with 60% being female. The mean Der p wheal diameter was 9.4 mm (SD 4.4). After one year of treatment, the composite score median (IQR) in the HDM SCIT group and the placebo group was 0.75 (0.50-1.13) and 0.63 (0.50-1.25), respectively (p > 0.05). Both groups exhibited a significant mean change in the composite score from baseline (p < 0.001), but there was no significant difference between the groups. The median (IQR) serum Der p-specific immunoglobulin G4 level significantly increased only in the HDM SCIT arm (p ≤ 0.001). CONCLUSION: One-year HDM SCIT significantly reduced both symptoms and medication use in HDM-allergic rhinitis patients. However, the changes were not significantly different from those in the placebo group, who also received an INCS at baseline. A longer-term study is warranted to assess disease modification factors.